Non-Invasive Brain Implants: Neuralink Alternative
- A brain-computer interface (BCI) developed by Precision Neuroscience offers new hope for individuals with paralysis.
- Ben Rapoport, cofounder and chief science officer at Precision Neuroscience, emphasized that critical brain activity is concentrated in the cortex, the brain's outermost layer.
- The company's technology involves a thin film with 1,024 electrodes placed on the brain surface in the area controlling movement, particularly the hand.
Discover how Precision Neuroscience is revolutionizing brain-computer interfaces (BCIs) as a potential alternative to invasive neural implants. This innovative approach targets the brain’s surface, offering a less intrusive method to restore movement and independence in paralyzed patients. The company’s thin-film technology, featuring 1,024 electrodes, empowers users to control cursors, access the internet, and engage in various activities. News Directory 3 provides deeper coverage.With FDA clearance secured and critically important funding, Precision Neuroscience is poised to advance the field. These less invasive brain implants present a focused approach on treating neurological diseases. Human trials are imminent! What’s next for this groundbreaking technology?
Brain-Computer Interface Advances Paralysis treatment
Updated June 28, 2025
A brain-computer interface (BCI) developed by Precision Neuroscience offers new hope for individuals with paralysis. The New York-based startup is pioneering a less invasive approach to neural implants, focusing on the brain’s surface to record activity.
Dr. Ben Rapoport, cofounder and chief science officer at Precision Neuroscience, emphasized that critical brain activity is concentrated in the cortex, the brain’s outermost layer. This challenges the misconception that deep-penetrating electrodes are necessary to extract meaningful data.
The company’s technology involves a thin film with 1,024 electrodes placed on the brain surface in the area controlling movement, particularly the hand. This allows patients to control cursors, type, access the internet, use PowerPoint, play games and word process, Rapoport said.
Precision Neuroscience received FDA clearance for a portion of its wireless BCI in April and has secured $155 million in funding since its launch in 2021. The company is part of the Implantable BCI Collaborative Community, launched in partnership with the FDA in 2024.
While companies like Elon Musk’s Neuralink aim for a “symbiosis” between the human brain and AI, Precision Neuroscience focuses on treating neurological diseases. The company has tested its temporary device in over 40 patients in early clinical studies. Human studies of its permanently implanted devices are planned for the coming year, pending internal validation and FDA approval, Rapoport said.
“We implant modules of 1,024 electrodes on the brain surface in the area that controls movement, especially the hand,” Rapoport said.
What’s next
Precision Neuroscience aims to restore a significant level of independence and economic self-sufficiency for paralyzed individuals, enabling them to hold jobs and fully participate in the workplace, according to Rapoport.